Aleš Obr
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 5%
- CAR-T cell therapy research
- COVID-19 and healthcare impacts
Papers in
-
- Lymphoma Diagnosis and Treatment 17
- Genetics 10
- Chronic Lymphocytic Leukemia Research 9
- Co-authors
- Johannes Duell (5 shared papers)Sumeet Ambarkhane (5 shared papers)Wojciech J. Jurczak (5 shared papers)Gilles Salles (4 shared papers)Johannes Weirather (4 shared papers)Gianluca Gaïdano (4 shared papers)Kami J. Maddocks (4 shared papers)Eva M. González-Barca (4 shared papers)
- Journals
- Hematological Oncology (6 papers)Haematologica (2 papers)Journal of Hematology & Oncology (1 paper)EClinicalMedicine (1 paper)Cancer Medicine (1 paper)
- Partner nations
- CzechiaGermanyUnited Kingdom
In The Last Decade
Aleš Obr
24 papers receiving 1.0k citations
Aleš Obr's Hit Papers
Peers
Comparison fields: 5 of 51
- Pathology and Forensic Medicine 527
- Oncology 670
- Genetics 181
- Infectious Diseases 157
- Dermatology 53
Countries citing papers authored by Aleš Obr
This map shows the geographic impact of Aleš Obr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleš Obr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleš Obr more than expected).
Fields of papers citing papers by Aleš Obr
This network shows the impact of papers produced by Aleš Obr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleš Obr. The network helps show where Aleš Obr may publish in the future.
Co-authors
The 25 scholars most cited alongside Aleš Obr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study Hit paper breakdown → | 2020 | 426 |
| 2 | COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) Hit paper breakdown → | 2021 | 239 |
| 3 | 2021 | 111 | |
| 4 | 2020 | 34 | |
| 5 | 2020 | 34 | |
| 6 | 2018 | 27 | |
| 7 | 2022 | 25 | |
| 8 | 2021 | 20 | |
| 9 | 2024 | 20 | |
| 10 | 2017 | 18 | |
| 11 | 2020 | 15 | |
| 12 | 2023 | 12 | |
| 13 | 2021 | 11 | |
| 14 | 2018 | 9 | |
| 15 | 2020 | 9 | |
| 16 | 2018 | 6 | |
| 17 | 2019 | 5 | |
| 18 | 2022 | 4 | |
| 19 | 2021 | 3 | |
| 20 | 2020 | 2 |
About Aleš Obr
Aleš Obr is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Neurology and Infectious Diseases, having authored 25 papers that have together received 1.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (9 papers), CAR-T cell therapy research (7 papers), Viral-associated cancers and disorders (5 papers), COVID-19 Clinical Research Studies (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (527 citations), Oncology (670 citations), Genetics (181 citations), Infectious Diseases (157 citations) and Dermatology (53 citations). Aleš Obr has collaborated with scholars based in Czechia, Germany and United Kingdom. Frequent co-authors include Johannes Duell, Sumeet Ambarkhane, Wojciech J. Jurczak, Gilles Salles, Johannes Weirather, Gianluca Gaïdano, Kami J. Maddocks, Eva M. González-Barca, Maren Dirnberger‐Hertweck and Anna Marina Liberati. Their work appears in journals such as Hematological Oncology, Haematologica, Journal of Hematology & Oncology, EClinicalMedicine and Cancer Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.